SCHEMBL1882907

SCHEMBL1882907

CCCn1cnc(CCNC(=O)Nc2nc(C)c(-c3cc(C)nc(C)n3)s2)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 13/20 0.50
PIK3CA P42336 6/20 0.50
PRKDC P78527 2/20 0.43
CYP2C9 P11712 1/20 0.43
KCNH2 Q12809 1/20 0.43
NTRK1 P04629 1/20 0.38
PIK3CD O00329 2/20 0.37
PIK3CB P42338 2/20 0.37
PI4KB Q9UBF8 2/20 0.37
CLK1 P49759 1/20 0.37
CLK2 P49760 1/20 0.37
JAK2 O60674 1/20 0.36
LCK P06239 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
CPB2 Q96IY4 3/20 0.34
CPB1 P15086 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1892522 0.93 PIK3CG (0.49) PIK3CGPIK3CAPRKDCCYP2C9KCNH2
SCHEMBL1885504 0.86 PIK3CG (0.45) PIK3CGPIK3CAPRKDCCYP2C9KCNH2
SCHEMBL12991524 0.82 PIK3CG (0.57) PIK3CGPIK3CAPRKDCCYP2C9KCNH2
SCHEMBL1885011 0.81 PIK3CG (0.46) PIK3CGPIK3CAPRKDCCYP2C9KCNH2
SCHEMBL1885502 0.80 PIK3CG (0.52) PIK3CGPIK3CAPRKDCCYP2C9KCNH2
SCHEMBL1883557 0.80 PIK3CG (0.44) PIK3CGPIK3CAPRKDCCYP2C9KCNH2
SCHEMBL1784961 0.79 PIK3CG (0.52) PIK3CGPIK3CAPRKDCCYP2C9KCNH2
SCHEMBL1787858 0.77 PIK3CG (0.65) PIK3CGPIK3CAPRKDCCYP2C9KCNH2
SCHEMBL12991696 0.75 PIK3CG (0.59) PIK3CGPIK3CAPRKDCCYP2C9KCNH2
SCHEMBL1887774 0.75 PIK3CG (0.47) PIK3CGPIK3CAPRKDCCYP2C9KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2157091-B1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2015-06-10 EP disclosed
US-20130172349-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2013-07-04 US disclosed
US-8404684-B2 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2013-03-26 US disclosed
US-20110105535-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG 2011-05-05 US disclosed
EP-2157091-A1 Inhibitors of phosphatidylinositol 3-kinase Novartis AG (CH) 2010-02-24 EP disclosed
EP-1622897-B1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2009-10-14 EP disclosed
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2007-02-08 US disclosed
EP-1622897-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE Novartis AG (CH) 2006-02-08 EP disclosed
WO-2004096797-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE NOVARTIS AG (CH) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase PIK3CA, PIP4K2C, PIP4K2B PIK3CG 10/4885PIK3CA 1/4885PRKDC 133/4885
US-20110105535-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CA, PIK3CD, PIP4K2C PIK3CG 8/4885PIK3CA 1/4885PRKDC 125/4885
US-20130172349-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CA, PIK3CD, PIP4K2C PIK3CG 8/4885PIK3CA 1/4885PRKDC 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.